Li Junqing, Wu Feiran, Su Li, Zhu Huimin, Yao Jie, Zhang Meng
Minimally Invasive Spinal Surgery Center, Luoyang Orthopedic-Traumatological Hospital of Henan Province (Henan Provincial Orthopedic Hospital), Zhengzhou, Henan 450018, P.R. China.
Department of Orthopedics, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, Henan 450003, P.R. China.
Oncol Lett. 2023 Jul 20;26(3):383. doi: 10.3892/ol.2023.13969. eCollection 2023 Sep.
Previous studies have demonstrated the involvement of the solute carrier family 17 member 9 () in certain types of cancer; however, the precise role of is not well defined. In the present study, a comprehensive analysis was performed to determine the involvement of in a pan-cancer panel. First, data on expression levels from publicly available databases were obtained to determine expression profiles in various types of cancer. Next, the involvement of in the prognosis of patients, stemness indices and the immune microenvironment was examined in 34 types of cancer. Furthermore, CCK-8 and colony-formation assays were performed to determine the effect of on osteosarcoma (OSS) cells. In a pan-cancer panel, a difference in expression levels was observed in the tumor tissues as compared with healthy tissues. Furthermore, survival analysis revealed a significant association between expression levels and the prognosis of patients with various cancer types, including adrenocortical carcinoma, kidney renal clear cell carcinoma, glioblastoma, kidney renal papillary cell carcinoma, low grade glioma, liver hepatocellular carcinoma, mesothelioma, lung adenocarcinoma, skin cutaneous melanoma, uveal melanoma, stomach adenocarcinoma and OSS. The results of the present study revealed correlations between stemness indices, tumor immunity and expression levels. Furthermore, univariate and multivariate Cox regression analyses indicated that may be utilized as an independent risk factor for overall survival of patients with OSS. experiments demonstrated that promotes the proliferation and viability of OSS cells. Taken together, the results of the present study suggest an association between and the prognosis of patients as well as tumor immunity in various cancer types. may serve as a novel prognostic biomarker and target for improving the prognosis of patients with OSS.
先前的研究已证明溶质载体家族17成员9（）参与某些类型的癌症；然而，的精确作用尚未明确界定。在本研究中，进行了全面分析以确定在泛癌组中的参与情况。首先，从公开可用数据库中获取关于表达水平的数据，以确定在各种类型癌症中的表达谱。接下来，在34种癌症类型中研究了在患者预后、干性指数和免疫微环境中的参与情况。此外，进行了CCK - 8和集落形成试验，以确定对骨肉瘤（OSS）细胞的影响。在泛癌组中，与健康组织相比，在肿瘤组织中观察到表达水平存在差异。此外，生存分析显示表达水平与包括肾上腺皮质癌、肾透明细胞癌、胶质母细胞瘤、肾乳头状细胞癌、低级别胶质瘤、肝细胞肝癌、间皮瘤、肺腺癌、皮肤黑色素瘤、葡萄膜黑色素瘤、胃腺癌和OSS在内的各种癌症类型患者的预后之间存在显著关联。本研究结果揭示了干性指数、肿瘤免疫与表达水平之间的相关性。此外，单因素和多因素Cox回归分析表明，可作为OSS患者总生存的独立危险因素。实验表明促进了OSS细胞的增殖和活力。综上所述，本研究结果表明与各种癌症类型患者的预后以及肿瘤免疫之间存在关联。可作为一种新型的预后生物标志物以及改善OSS患者预后的靶点。
